Liver News and Research

RSS

Hepatitis C rather than Donor Risk Index is major contributor to poor graft survival in transplant patients

The Donor Risk Index, which assesses donor characteristics impacting liver transplantation outcomes, does not bear the same impact on outcomes on a small scale as is suggested from large-scale, national data.

17 Aug 2010

JDRF announces key step on road to artificial pancreas

JDRF announced today another important step on the road to the development of an artificial pancreas - an automated system to better manage the blood sugar of people with type 1 diabetes - with the establishment of a research program to speed the development of faster-acting insulin.

17 Aug 2010

High exposure to estrogens may cause gall bladder cancer: Research

A very aggressive disease with a poor prognosis, gallbladder cancer may be connected to higher exposure to estrogens, according to a group of researchers at the University of Houston (UH). Dr. Jan--ke Gustafsson, Robert A. Welch Professor in UH's biology and biochemistry department, described his team's findings in a paper titled "Estrogen-dependent gallbladder carcinogenesis in LXRβ-/- female mice" appearing in a recent issue of the journal Proceedings of the National Academy of Sciences, one of the world's most-cited multidisciplinary scientific serials.

17 Aug 2010

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

Cumberland Pharmaceuticals Inc. ,a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announces financial results for the second quarter ending June 30, 2010, and provides revenue guidance for full year 2010.

17 Aug 2010

FDA grants Microsulis Medical 510(k) clearance for Acculis Accu2i percutaneous microwave tissue ablation system

Microsulis Medical Limited, the leading company in microwave technology for medical devices, today announced that the U.S. Food and Drug Administration (FDA) has provided the company 510(k) clearance to market the Acculis Accu2i percutaneous microwave tissue ablation (pMTA) system for the coagulation of soft tissue during surgical procedures.

16 Aug 2010

August is National Immunization and Cataract Awareness Month

Childhood immunizations keep our children safe from a number of serious diseases. This is a good time of year to make sure your child is up-to-date on all of his/her immunizations. Continue reading to find out which vaccines the Centers for Disease Control and Prevention (CDC) recommend for children 6 and under.

16 Aug 2010

New T cell engineering approach can improve success rate of immune-cell therapies

Clinical trials using patients' own immune cells to target tumors have yielded promising results. However, this approach usually works only if the patients also receive large doses of drugs designed to help immune cells multiply rapidly, and those drugs have life-threatening side effects. Now a team of MIT engineers has devised a way to deliver the necessary drugs by smuggling them on the backs of the cells sent in to fight the tumor. That way, the drugs reach only their intended targets, greatly reducing the risk to the patient.

16 Aug 2010

Obesity diabetes link found

Melbourne researchers from the Walter and Eliza Hall Institute have found that inflammatory cells in fat tissue cause the body to become resistant to the effects of insulin – a common precursor to type II diabetes.

16 Aug 2010

Statin drugs can neutralise heart disease dangers of fatty food: Study

Fast food outlets could provide statin drugs free of charge so that customers can neutralise the heart disease dangers of fatty food, researchers at Imperial College London suggest in a new study published this week.Statins reduce the amount of unhealthy "LDL" cholesterol in the blood. A wealth of trial data has proven them to be highly effective at lowering a person's heart attack risk.

13 Aug 2010

Merlin protein controls adult cell activity to cause liver cancer

A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer. In the August 15 issue of Genes & Development, a Massachusetts General Hospital (MGH) research team describes finding that the protein called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls the activity of adult stem cells that give rise to the two major types of liver cells.

13 Aug 2010

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

12 Aug 2010

Clinical cases that use IQQA-Liver for operative assessments exceed 1000: EDDA Technology

EDDA Technology announced today that the number of clinical cases evaluated for pre- and post- operative assessment using IQQA-Liver in hospitals has exceeded 1000 examinations, since the first commercial system installation in Q2 2009. EDDA's IQQA-Liver, now marketed worldwide, is a comprehensive workflow solution supporting modern multidisciplinary liver imaging evaluation and management.

12 Aug 2010

Einstein College receives grant to develop stem cell-based therapies

Scientists at Albert Einstein College of Medicine of Yeshiva University have received a five-year, $10.8 million grant to develop stem cell-based therapies that could be used to mitigate radiation-induced gastrointestinal syndrome - part of acute radiation syndrome (ARS) - for military personnel, first responders and the general public. The Einstein research, funded by the federal Centers for Medical Countermeasures Against Radiation, is part of a program coordinated by the National Institute of Allergy and Infectious Diseases.

12 Aug 2010

Needle-free natural vaccine against malaria: Research

A study published in the journal Science Translational Medicine proposes that preventative treatment with affordable and safe antibiotics in people living in areas with intense malaria transmission has the potential to act as a 'needle-free' natural vaccine against malaria and may likely provide an additional valuable tool for controlling and/or eliminating malaria in resource-poor settings.

12 Aug 2010

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, today reported its financial results for the second quarter ended June 30, 2010.

11 Aug 2010

NKTreg white blood cells migrate into liver, suppress immune responses: Research

After a transplant - and to assure that the new organ is not rejected - patients are put on life-long therapy to suppress their immune system, which, nevertheless, needs to be left intact enough to be able to defend the body against all kinds of disease. A tricky balance as the many rejected organs attest. But a discovery by Maria Monteiro and Luis Graça, two Portuguese scientists, could change all this, at least for the liver.

11 Aug 2010

Two NJIT biomedical researchers receive Coulter Foundation Translational Awards for patent application

Two NJIT biomedical researchers have received the prestigious Coulter Foundation Translational Awards for promising patent applications that may some day extend peoples' lives.The Coulter program provides funding for professors in established biomedical engineering departments within the U.S. Initial funding for each professor will be at least $200,000 over a two-year period.

11 Aug 2010

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Genentech, Inc., a member of the Roche Group, announced today that the U.S. Food and Drug Administration (FDA) approved increasing the length of therapy with Valcyte (valganciclovir hydrochloride) in adult kidney transplant patients at high risk for cytomegalovirus (CMV) disease.

11 Aug 2010

Pharmasset third-quarter net loss increases to $16.0 million

Pharmasset, Inc., a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, today reported financial results and operational highlights for the quarter ended June 30, 2010.

10 Aug 2010

Synta second-quarter net loss increases to $9.1 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported financial results for the quarter ended June 30, 2010.

10 Aug 2010

Liver News and Research

Hepatitis C rather than Donor Risk Index is major contributor to poor graft survival in transplant patients

JDRF announces key step on road to artificial pancreas

High exposure to estrogens may cause gall bladder cancer: Research

Cumberland Pharmaceuticals reports 9% increase in second quarter 2010 net revenue

FDA grants Microsulis Medical 510(k) clearance for Acculis Accu2i percutaneous microwave tissue ablation system

August is National Immunization and Cataract Awareness Month

New T cell engineering approach can improve success rate of immune-cell therapies

Obesity diabetes link found

Statin drugs can neutralise heart disease dangers of fatty food: Study

Merlin protein controls adult cell activity to cause liver cancer

Fast food outlets can provide statin drugs to help customers neutralise heart disease: Researchers

Clinical cases that use IQQA-Liver for operative assessments exceed 1000: EDDA Technology

Einstein College receives grant to develop stem cell-based therapies

Needle-free natural vaccine against malaria: Research

Rxi Pharmaceuticals second-quarter net loss decreases to $2.1 million

NKTreg white blood cells migrate into liver, suppress immune responses: Research

Two NJIT biomedical researchers receive Coulter Foundation Translational Awards for patent application

FDA approves longer Valcyte therapy for CMV disease in adult kidney transplant patients

Pharmasset third-quarter net loss increases to $16.0 million

Synta second-quarter net loss increases to $9.1 million

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News